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Abstract
Background: We reported previously on the emergence and clinical implications of simian immunodeficiency virus
(SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune
responses in suppressing viremia during tenofovir therapy. Because of significant sequence differences between SIV and
HIV-1 RT that affect drug susceptibilities and mutational patterns, it is unclear to what extent findings with SIV can be
extrapolated to HIV-1 RT. Accordingly, to model HIV-1 RT responses, 12 macaques were inoculated with RT-SHIV, a
chimeric SIV containing HIV-1 RT, and started on prolonged tenofovir therapy 5 months later.
Results: The early virologic response to tenofovir correlated with baseline viral RNA levels and expression of the MHC
class I allele Mamu-A*01. For all animals, sensitive real-time PCR assays detected the transient emergence of K70E RT
mutants within 4 weeks of therapy, which were then replaced by K65R mutants within 12 weeks of therapy. For most
animals, the occurrence of these mutations preceded a partial rebound of plasma viremia to levels that remained on
average 10-fold below baseline values. One animal eventually suppressed K65R viremia to undetectable levels for more
than 4 years; sequential experiments using CD8+ cell depletion and tenofovir interruption demonstrated that both CD8+
cells and continued tenofovir therapy were required for sustained suppression of viremia.
Conclusion: This is the first evidence that tenofovir therapy can select directly for K70E viral mutants in vivo. The
observations on the clinical implications of the K65R RT-SHIV mutants were consistent with those of SIVmac251, and
suggest that for persons infected with K65R HIV-1 both immune-mediated and drug-dependent antiviral activities play a
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role in controlling viremia. These findings suggest also that even in the presence of K65R virus, continuation of tenofovir
treatment as part of HAART may be beneficial, particularly when assisted by antiviral immune responses.
Background
Tenofovir (9-[2-(phosphonomethoxy)propyl]adenine;
PMPA) is a commonly used antiretroviral compound
which selects for the K65R mutation in reverse tran-
scriptase (RT); this mutation is associated with a 2- to 5-
fold reduced in vitro susceptibility to tenofovir [1,2]. Many
tenofovir-containing regimens induce strong and long-
lasting suppression of viremia in the majority of persons,
with a low occurrence of the K65R mutation [1,3-5]; the
emergence of K65R mutants in such patients was not
always associated with a viral rebound [1,5,6]. However,
a lower virologic success rate has been observed when ten-
ofovir was used in specific combinations with other drugs
with overlapping resistance profile (e.g., lamivudine,
didanosine and abacavir), and the K65R mutation was
found in approximately 50% of patients with a less-than-
desired virologic response on such regimens [6-11].
Although much progress has been made [12], many unre-
solved questions remain regarding the exact virulence and
clinical implications of drug-resistant viral mutants, and
how to use this information to make treatment decisions.
This is also true for K65R viral mutants. While the K65R
mutation reduces replication fitness of HIV-1 in vitro rela-
tive to wild-type virus [13], it is unclear to which extent
this can be extrapolated to virus replication fitness in vivo,
especially when K65R is accompanied by other mutations
in RT; some mutations may be compensatory (to improve
replicative capacity), while the combination of K65R with
certain other drug-selected mutations may be deleterious
for viral replicative capacity (e.g., L74V, certain thymi-
dine-analogue mutations), or may restore viral suscepti-
bility to other compounds of the drug regimen [14-17]. It
is also unclear whether the detection of K65R HIV-1
mutants is a valid criterion for withdrawing tenofovir
from the patient's regimen, as it is possible that tenofovir
still exerts some residual antiviral activity in vivo against
replication of K65R HIV-1.
Simian immunodeficiency virus (SIV) infection of
macaques has been a useful animal model to study the
emergence, virulence and clinical implications of viral
mutants during drug treatment [18]. Prolonged tenofovir
monotherapy of macaques infected with virulent
SIVmac251 resulted in the emergence of mutants with the
K65R mutation in RT [19,20]. In the absence of tenofovir
treatment, these K65R SIV isolates replicated in vivo to
high levels and induced a disease course indistinguishable
from that of wild-type virus [21]. In the presence of teno-
fovir treatment, however, disease-free survival was
improved significantly, and some animals were able to
suppress viremia of K65R virus to low or undetectable lev-
els for 4 to more than 10 years [20-22]. Further experi-
ments, using in vivo CD8+ cell depletions and treatment
interruption, revealed that this suppression of K65R
viremia depended on strong CD8+ cell-mediated immune
responses, but that continued tenofovir therapy was also
still necessary [20]. However, even when K65R viremia
was not suppressed, continued tenofovir treatment was,
surprisingly, associated with clinical benefits (i.e., disease-
free survival) that were larger than predicted based on
viral RNA levels and standard immune markers [22].
Because there are some important differences in the
amino acid sequence of HIV-1 and SIV RT which affect
susceptibilities and the mutational patterns to antiviral
drugs [23], it is unclear to what extent these findings from
the SIV model regarding the in vivo emergence, virulence
and clinical implications of K65R viral mutants during
tenofovir treatment can be extrapolated to HIV-1 RT.
Some experimental procedures (such as CD8+ cell deple-
tions, or prolonged tenofovir monotherapy), however, are
not ethically or logistically feasible to study in HIV-1
infected humans. Because there is so far no optimal ani-
mal model that uses HIV-1, the currently best approach to
unravel such questions about HIV-1 RT is the use of
macaques infected with RT-SHIV, a chimeric virus consist-
ing of SIVmac239 in which the RT gene is replaced by the
counterpart of HIV-1 [24,25]. While RT-SHIV is virulent in
macaques, the early studies (which used small animal
numbers) found that viremia and the rate of disease pro-
gression were variable and on average lower than that
observed with SIVmac239 or with other virulent SIV iso-
lates, such as SIVmac251 [20,25-28]; this is likely because
the insertion of a foreign RT into SIV affected its replica-
tive ability [24]. Thus, a long-term study was performed to
address the following questions through sequential exper-
iments: (i) does in vivo passage of RT-SHIV lead to higher
or more consistent virulence, (ii) does prolonged tenofo-
vir treatment initiated during chronic RT-SHIV infection
lead to the emergence of K65R viral mutants, (iii) what are
the clinical implications of K65R mutants, and (iv) what
is the role of CD8+ cells and continued tenofovir treat-
ment in controlling viremia of K65R RT-SHIV?
The current report is the first one to demonstrate that dur-
ing prolonged tenofovir therapy, RT-SHIV infected ani-
mals developed first K70E mutants, which were then
replaced by K65R mutants. Further experiments in one
animal that suppressed K65R viremia to undetectable lev-Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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els demonstrated that, similarly to the findings in the
SIVmac251 model, both CD8+ cell-mediated antiviral
immune responses and continued tenofovir therapy were
important to obtain maximal suppression of RT-SHIV
viremia. This suggests that maintaining tenofovir as part
of HAART, particularly when CD8+ cell-mediated
immune responses are good and no better therapies are
available, may still offer clinical benefits to persons
infected with K65R mutants.
Results
In vivo passage of RT-SHIV and establishment of 
persistent infection
Although the molecular clone of RT-SHIV is virulent in
macaques, earlier studies found that infection resulted in
a variable peak and set-point of viral RNA levels in plasma
[24,26-28]. In an attempt to further increase its virulence,
the cloned virus was subjected to 2 sequential in vivo pas-
sages (Fig. 1). A first group of 3 animals (group A) was
inoculated intravenously with 105 TCID50 of in vitro prop-
agated RT-SHIV. Plasma collected two weeks after infec-
tion was pooled and 0.6 ml of this pool (containing ~19
× 106 viral RNA copies; ~1,400 TCID50) was administered
intravenously to a second group of 4 animals (Fig. 1,
group B). The same procedure was repeated, and 0.6 ml
pooled plasma collected from group B animals at 2 weeks
of infection (~10 × 106 viral RNA copies; ~1,000 TCID50)
was injected intravenously into 5 animals (Fig. 1, group
C). Peak virus levels for animals of all 3 groups were
observed at 1 to 2 weeks after infection and ranged from
9 to 43 million copies RNA per ml plasma (Fig. 1A), and
2,200 to 32,000 TCID50 per million PBMC (data not
shown). The rapid serial passage in macaques did not
have any detectable effect. The 3 animal groups had simi-
lar viral RNA levels in plasma and infectious titers in
PBMC, and a similar decline in absolute counts and per-
centages of CD4+ T lymphocytes and CD4+/CD8+ T cell
ratios during the first 20 weeks of infection (two-way
ANOVA: p values of passage effect >0.05; Fig. 1). During
the first 20 weeks of infection, all 12 animals had a
decrease in absolute CD4+ T cell counts (mean loss of 927
(range 480–1590) cells per μl; Fig. 2B); this meant a
median decrease of 55% (range 28–83%) of their abso-
lute CD4+ T cell counts. All 12 animals mounted strong
humoral immune responses to SIV, as the SIV-specific IgG
titers in plasma (measured by ELISA) were > 102,400 by
eight weeks of infection (data not shown). There was no
detectable difference among the three groups in response
to subsequent tenofovir treatment and disease-free sur-
vival, and accordingly the groups are combined for the
presentation of the remainder of the study.
Tenofovir monotherapy of RT-SHIV infected macaques: 
early virologic and immunologic responses
Untreated RT-SHIV infected macaques have generally lit-
tle change in viremia once a viral set-point is established
after ~8 to 12 weeks of infection [25,26,29]. In the current
study, the 12 RT-SHIV animals were started on tenofovir
monotherapy (10 mg/kg, subcutaneously once daily) at
approximately 20 weeks of infection. This starting dose
was selected because it is pharmacokinetically similar
(based on plasma AUC levels of ~20 μg.h/ml) to the intra-
venous tenofovir regimen of the initial human clinical tri-
als [30]. Tenofovir treatment was associated with an
average 10-fold decrease in viral RNA levels after 1 week
of treatment (Fig. 2A). However, there was much individ-
ual variability; 10 animals had a decrease in plasma viral
RNA levels (mean decrease: 21-fold; range: 2 to 53-fold),
while the remaining 2 animals (numbers 30842 and
30478; Fig. 3) had no decrease after 1 week of treatment.
Infectious virus titers in PBMC showed similar patterns as
the plasma viral RNA levels (data not shown). The early
effect of tenofovir therapy on the percentage of CD4+ T
lymphocytes in peripheral blood was variable, as only
half of the animals showed a relative increase of ≥ 3%
within 2 weeks of therapy (Fig. 3). However, relative to
the baseline value at the onset of tenofovir therapy, after
2 weeks of treatment all 12 animals had an increase in
total lymphocyte counts (median increase of 51% (range
22–272%; p = 0.001, two-tailed paired t test), and 11 ani-
mals had an increase in absolute CD4+ T cell counts
(mean change of + 469 (range from -149 to +1291) cells
per μl; p = 0.002, two-tailed paired t test; Fig. 2B), which
meant a median increase in absolute CD4+ T cell counts
of 71% (range of relative change: -21 to +183%). This sig-
nificant increase in absolute CD4+ T cell counts was tran-
sient, as values returned to pre-therapy baseline values
after 12 weeks of tenofovir therapy (32 weeks of infection;
Fig. 2B; two-tailed paired t test p values ≥ 0.05). Absolute
CD4+ T cell counts then stabilized for most animals until
they declined concomitantly with the development of
clinical disease symptoms.
Three of the 12 animals expressed the major histocompat-
ibility complex (MHC) class I allele Mamu-A*01; 4 other
animals expressed the MHC class I Mamu-B*01 allele.
Although there was no significant effect of the presence of
either one of these alleles and viremia during the first 20
weeks of infection (prior to tenofovir therapy), Mamu-
A*01-positive animals responded initially to tenofovir
therapy with lower viral RNA levels than Mamu-A*01-
negative animals (first 4 weeks of treatment, two-way
ANOVA, effect of Mamu-A*01 p = 0.02; Fig. 4A). But
between 8 to 20 weeks of tenofovir treatment (i.e., 28 to
40 weeks of infection), concomitant with the detection of
viral mutants (see below), there was no significant differ-Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
Page 4 of 22
(page number not for citation purposes)
ence in viremia between Mamu-A*01-positive and -nega-
tive animals anymore (two-way ANOVA, p = 0.46).
We examined whether other baseline markers at the onset
of tenofovir therapy were predictive of the early virologic
response. The magnitude of the early virologic response
(i.e., fold decrease of viremia after 1 week of treatment)
correlated negatively with baseline viral RNA levels (Pear-
son r = -0.62, two-tailed p = 0.03; Fig. 5B), and negatively
with baseline % CD4+ T lymphocytes (Pearson r = -0.84;
two-tailed p = 0.0007; Fig. 5C), but not with % CD8+ T
lymphocytes (p = 0.11; Fig. 5D). Baseline viral RNA corre-
lated positively with % CD4+ T lymphocytes (Pearson r =
0.66; two-tailed p = 0.019; Fig. 5A).
Selection of K70E followed by K65R mutation in RT during 
prolonged tenofovir monotherapy
For 9 of the 10 animals for which viremia decreased fol-
lowing the onset of tenofovir therapy, the nadir of plasma
viral RNA levels was reached after 2 to 4 weeks of treat-
Serial in vivo passage of RT-SHIV: effect on virulence Figure 1
Serial in vivo passage of RT-SHIV: effect on virulence. A high dose of RT-SHIV (105 TCID50), propagated in vitro in 
CEMx174 cells, was inoculated intravenously in 3 animals (group A). Plasma collected 2 weeks later was pooled and adminis-
tered intravenously to 4 animals (group B). The same procedure was repeated for the final passage into 5 animals (group C). 
There were no significant differences between the 3 groups with regard to viral RNA levels (calculated after log-transforma-
tion; graph A), mean absolute CD4+ T lymphocytes counts/μl and % CD4+ T lymphocytes in peripheral blood, (graphs B, C). 
Error bars indicate SEM.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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ment (Fig. 3). Subsequently, there was a partial rebound
of viremia, although the average virus levels remained
approximately 10-fold below the baseline levels (i.e., at
the onset of tenofovir therapy; Fig. 2A). This rebound was
associated with the detection of RT mutations that were
not detectable prior to tenofovir treatment. Population
sequencing of virus isolates from PBMC revealed that the
2 most frequent mutations that emerged sequentially
early after tenofovir therapy were a lysine to glutamic acid
mutation at codon 70 (K70E; AAA to GAA) followed by
the K65R mutation (AAA to AGA)(table 1). Therefore,
more sensitive real-time PCR assays were developed to
detect and quantify these 2 mutants in viral RNA in
sequential plasma samples. While population genotyping
of DNA from PBMC-derived virus isolates detected K70E
mutants in only 10 animals, the real-time PCR method
detected K70E mutants in plasma RNA of all 12 animals
within 1 to 4 weeks (median 2 weeks) of tenofovir treat-
ment (Fig. 3, 6). For all 12 animals, the K65R mutation
became detectable in plasma viral RNA within 2 to 12
weeks of treatment (median time, 4 weeks). Due to its
high sensitivity for detecting low-frequency mutants, the
real-time PCR assay detected the K65R mutation prior to
its detection by population genotyping in 11 animals
(table 1). When both K65R and K70E were detected in
plasma viral RNA samples, direct sequencing of the muta-
tion-specific real-time PCR amplicons demonstrated that
the 2 mutations were on separate genomes (Fig. 7A). By
12 weeks of treatment, K70E became undetectable prior to
or coinciding with the establishment of the K65R muta-
tion in 10 of the 12 animals (Fig. 6).
The K65R mutation resulted in approximately 5-fold
reduced in vitro susceptibility to tenofovir (data not
shown). Other RT mutations, which were likely compen-
satory mutations, were also detected in viruses by popula-
tion sequencing (table 1). Some mutations (e.g. V75I/L,
E194K, G196R, L214F) were already present in some
viruses obtained prior to tenofovir therapy, and most have
previously been described in RT-SHIV isolates obtained
from untreated macaques [25,31-33]. The mutations
most commonly observed (sometimes transiently) after
the detection of K65R included K20R (3 animals), M41L
(3 animals), S68G/K/N (12 animals), K70H/N/T/Q (9
animals), W88S (6 animals), Y115F (9 animals), F116W
(6 animals), V118I (3 animals), I178M (6 animals),
L214F (11 animals), and K219Q/R/E/N/D/H/G (7 ani-
mals) (table 1). Sequencing of mutation-specific ampli-
cons revealed that the codon 68 mutations were
associated with K65R sequences and not K70E (Fig. 7B);
the codon 68 mutations may thus represent mutations
that compensate for the replicative fitness cost of K65R, as
has been suggested for HIV-1 [5,34]. There was no obvi-
ous causative association between these additional RT
mutations and the rate of disease progression. Instead,
animals that had persistent viremia and longer survival
Effect of tenofovir therapy on mean viral RNA levels and CD4+ T lymphocyte counts Figure 2
Effect of tenofovir therapy on mean viral RNA levels and CD4+ T lymphocyte counts. (A) Following tenofovir 
treatment (vertical dotted line), the average viremia (mean +/- SEM, calculated after log transformation) declined to approxi-
mately 1 log below pre-therapy baseline levels; note that the length of the SEM bars indicates larger variability of viremia after 
tenofovir therapy than before treatment (as shown in the individual graphs in figure 3). (B). The time course of CD4+CD3+ T 
lymphocyte counts in peripheral blood of the 12 animals is presented as absolute values (mean +/- SEM) along the left Y-axis; in 
addition, for each individual animal, the change in CD4+ T cell counts relative to its pre-infection value (time zero) was calcu-
lated, and the mean +/- SEM of these changes is presented along the right Y-axis. Both analyses gave (as expected) identical sta-
tistical conclusions.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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Individual data of plasma viral RNA levels and percentages of CD4+ T lymphocytes Figure 3
Individual data of plasma viral RNA levels and percentages of CD4+ T lymphocytes. Twelve RT-SHIV infected juve-
nile macaques were started on tenofovir treatment (10 mg/kg subcutaneously, once daily) at approximately 20 weeks of infec-
tion (vertical dotted line). Changes in tenofovir dosage regimens (in mg/kg) are indicated in the boxes along the X-axis. Viral 
RNA levels in plasma (in log-transformed copy number per ml plasma) are presented along the left Y-axis, while the % CD4+ T 
lymphocytes in peripheral blood is presented along the right Y-axis. The earliest detection of the K70E or K65R mutation in 
viral RNA in plasma virus by real-time RT-PCR is indicated (see Figure 6 for more details). Animals are arranged according to 
disease-free survival (which is indicated after each animal number). The presence or absence of the expression of the MHC I 
alleles Mamu-A*01 and Mamu-B*01 is indicated below each animal number.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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accumulated more mutations in RT than animals that had
a more rapid disease course; in other words, these addi-
tional mutations were not required for a relatively rapid
disease course. The tenofovir regimen was increased for
most animals at 40 weeks of infection from 10 to 20 mg/
kg to determine if higher drug levels would reduce viremia
or select for other patterns of RT mutations that have pre-
viously been reported to give higher levels of in vitro
resistance to tenofovir, such as T69S-insertion mutations
[35]. A pharmacokinetic study showed that the subcuta-
neous 20 mg/kg tenofovir regimen in this study gave
plasma AUC levels (mean +/- SD: 27.6 +/- 6.7 μg.h/ml;
range 18.7 to 39.2 μg.h/ml) slightly higher than those
observed in the human trials with intravenous tenofovir
dosing (22.5 +/- 9.8 μg.h/ml; [30]). This higher dosage
regimen did not result in any consistent changes in
viremia or any detectable changes in drug resistance pat-
terns (Fig. 3; table 1). Instead, the onset of glucosuria and
hypophosphatemia, signs indicative of renal toxicity asso-
ciated with high-dose tenofovir regimens [36], necessi-
tated a reduction of the individual dosage regimens to
safer low-dose maintenance regimens (Fig. 3).
The median disease-free survival of the tenofovir-treated
animals was 150 weeks (~3 years). With the caveat that
animal numbers per group were low, there was no signif-
icant difference in disease-free survival between Mamu-
A*01-positive and -negative animals (logrank test, p =
0.14; Fig. 4B). The two animals (animals 30842 and
30478) that did not have a reduction in viremia after the
start of tenofovir treatment developed life-threatening
immunodeficiency the earliest, at ~8–9 months of infec-
tion (Fig. 3). Nine chronically treated animals developed
fatal disease after 2 to 4 years of infection. For these 11
animals, the gross and histopathologic changes (includ-
ing lymphoid hyperplasia, lymphoid depletion and
opportunistic infections such as Cryptosporidium or
Pneumocystis carinii) were characteristic of terminal SIV-
induced immunodeficiency. The remaining animal,
number 30577, became a long-term survivor with unde-
Association of expression of MHC class I allele Mamu-A*01 with viremia and early virologic response to tenofovir therapy Figure 4
Association of expression of MHC class I allele Mamu-A*01 with viremia and early virologic response to teno-
fovir therapy. (A) No significant difference was detected between the 3 Mamu-A*01-positive and the 9 Mamu-A*01-negative 
animals with regard to viremia during the first 20 weeks of infection (two-way ANOVA, p = 0.86) or virus levels at the start of 
tenofovir treatment (vertical dotted line; two-tailed t-test: p = 0.29). However, during the first 4 weeks following the start of 
tenofovir treatment (dashed-line box), Mamu-A*01-positive animals had a bigger reduction in viral RNA levels than Mamu-
A*01-negative animals (two-way ANOVA, p = 0.02); there was no association of the Mamu-B*01 allele with viremia (data not 
shown). (B) Comparison of disease-free survival following tenofovir treatment revealed no significant difference between the 3 
Mamu-A*01-positive and 9 negative animals (logrank test, p = 0.14).Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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tectable viremia, even though its virus had the K65R
mutation in RT. Therefore, this animal is described subse-
quently in more detail.
The role of both CD8+ cells and tenofovir treatment in 
suppression of viremia of mutant viruses
Before the start of treatment, animal 30577 had a viral set-
point of ~106 viral RNA copies per ml plasma, and had the
expected changes associated with a virulent infection,
namely gradual decreases in percentages CD4+ T lym-
phocyte counts (< 15%; Fig. 3), absolute CD4+ T lym-
phocyte counts (< 500 per μl), and CD4+/CD8+ T
lymphocyte ratios (ratio < 1 from week 8 to week 20).
Thus, prior to tenofovir treatment, this animal was indis-
tinguishable from the other RT-SHIV infected animals of
this study. Following the onset of tenofovir treatment (at
20 weeks of infection), this animal had a rapid reduction
in viremia from 1.9 million to 51,000 viral RNA copies/
ml within one week; these kinetics suggest a half-life of
productively infected cells of 1.3 days, very similar to our
previous observations in SIVmac251-infected macaques
receiving tenofovir treatment during acute viremia [20].
Coinciding with the detection of K70E and K65R mutants
(Fig. 3, 8), plasma viremia rebounded from 40,000 (after
Correlations of baseline viral and immunologic parameters and early virologic response to tenofovir therapy Figure 5
Correlations of baseline viral and immunologic parameters and early virologic response to tenofovir therapy. 
Pre-treatment values of viral and immunologic parameters are baseline values at the onset of tenofovir treatment (i.e., ~20 
weeks of infection). The early virologic response is expressed as fold decrease of viremia (viral RNA levels in plasma) after 1 
week of tenofovir therapy. Spearman r and two-tailed p values are indicated for each graph. The pre-treatment viral RNA level 
correlated with the pre-treatment % CD4+ T lymphocytes (graph A), but did not correlate significantly with percentages of 
CD8+CD3+ T lymphocytes or CD20+ B lymphocytes (p = 0.40 and 0.12, respectively; data not shown). The early virologic 
response had significant correlations (p ≤ 0.05) with the pre-treatment viral RNA levels (graph B), % CD4+ T lymphocytes 
(graph C), and percentage and absolute counts of CD20+ B lymphocytes (data not shown). There was no correlation between 
the early virologic response to tenofovir and baseline lymphocyte counts, the percentages and absolute counts of CD3-CD8+ 
NK cells in peripheral blood, or SIV-specific IgG titers in plasma (data not shown).Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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Table 1: Mutations in RT detected in virus isolated from RT-SHIV infected macaques.
Animal number Time of Infection 
(weeks)
Codon 65 mutation Codon 70 mutation Other RT mutations
30007 21 (Tx) - - V75L, G196R, M357T/M
23 - - V75L, G196R
25 - K70E G196R, L214F, M357T
29 K65R/K - G196R, L214F, M357T
33 K65R - G196R, L214F
41 K65R - S68G, P150S, E194K, G196R, I202V, L214F
65 K65R K70N S68G, A98G, Y115F
93 K65R K70H V8I, S68G, A98G, Y115F, K154E, A158P, I159L, G196R, L214F, D218E, 
K219R, H221P
115 K65R K70H V8I, K45Q, S68G, A98G, Y115F, V179I, G196R, L214F, K219R, K275R, 
R277K, M357T
30162 21 (Tx) - - V75L, G196R, K275R
25 - - V75L, G196R, K275K/R
29 - - V75L, G196R, K275R
33 - - V75L, G196R, K275R
37 - - K22R, W88S, L214F
41 K65R - W88S, Y115F, E194K, L214F
65 K65R - S68S/N, W88S, Y115F
93 K65R K70T S68G, K70T, W88S, Y115F, K154E, A158P, L214F, K219Q
209 K65R K70T S68G, K70T, W88S, Y115F, T139A, I178M, L214F, H221Y, K275R, R277K, 
M357N
30478 21 (Tx) - - V75L, H208L, L214F
25 - - V75V/L, H208L. L214F
29 - K70E/K H208L, L214F
33 K65K/R K70E/Q/K G196R, L214F
37 K65R - S68N, G196R, L214F
41 K65R - S68N, G196R, L214F
30338 21 (Tx) - - G196R
22 - - V75L, G196R, L214F, K275R, M357T
23 - - V21I, V75L, G196R, L214F
25 - K70K/E V75L, G196R, L214F
29 K65R - G196R, L214F, M357T
33 K65R - G196R, L214F, K275R, M357T
41 K65R - S68N, Y115F, G196R, L214F
59 K65R K70Q S68N, Y115F
89 K65R K70Q K20R, Y115F, K154Q, A158T, I178M, E194K, G196R, L214F, K219Q
145 K65R K70Q V8I, K20R, M41L, S68G, W88S, Y115F, F116W, I178M, G196R, L214F, 
H221Y, K275R, R277K, P294Q, M357T
30339 21 (Tx) - - E194K, G196R,
25 WT - W88S, G196R, L214F, M357T
29 K65R - W88S, G196R, K275R, R277K, M357T
33 K65R - S68R, W88S, G196R, L214F, K275R
41 K65R - S68K, W88S, G196R, R199M, K219E
59 K65R - S68K, W88S, Y115F, K219E
89 K65R - K22R, K64R, S68K, W88S, Y115F, K154Q, A158P, I178M, G196R
150 K65R - T39A, K45Q, K64R, S68K, W88S, Y115F, I178M, V195L, G196K, K219G, 
H221Y, K275R, R277K, M357T
30340 21 (Tx) - - V75L, E194K, G196R,
22 - - V75L, G196R
23 - K70K/E G196R
25 - K70K/E G196R
29 K65R - G196R
33 K65R - G196R, L214F
41 K65R - S68G, Y115F, V118I, E194K, G196R, R199I
89 K65R - K20R, S68G, W88S, Y115F, G196R, R199I, L214F, H221Y
159 K65R K70Q S68K, W88S, Y115F, F116W, G196R, L214F, H221Y, S251N, R277K, M357T
30343 21 (Tx) - - G196R, K219NRetrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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22 - - G196R, K219N, K275R, M357T
23 - - G196R, K275R, M357T
25 K65K/R K70K/E G196R, K275R, M357T
41 K65R - S68N, G196R
59 K65R - S68N, Y115F, Y181C, K219N/D
89 K65R - S68N, W88S, Y115F, F116W, G196R, K219H
150 K65R K70H M41L, S68K, W88S, Y115F, F116W, V118I, I178M, G196R, K219H, K275R, 
R277K, M357T
30576 20 (Tx) - - V75I, E194K, G196R, L210V, L214F
21 - - V75L, G196R, L214F, K275R, G359S
22 - K70E/K G196R, L214F
24 - K70E/K G196R, E203G, L214F
28 - K70E/K G196R, L214F, M357T
32 K65R S68N, G196R, L214F, K275R, M357T
36 K65R S68N, G196R, L214F, M357T
40 K65R - S68N, I195T, G196R, L214F
53 K65R - S68N, Y115F
84 K65R K70N V8I, S68G, Y115F, F116W, Q145H, P150S, G196R, H208Q, L214F
178 K65R K70H V7I, K45Q, S68G, Y115F, F116W, R172S, K173Q, I178M, G196R, I202V, 
L214F, K219R, K275R, R277K, M357T
30577 20 (Tx) - - E194K, G196R
22 - - V75L, G196R, L214F
24 - K70E/K I178M, G196R, L214F
28 K65K/R K70E/K I178M, G196R
40 K65R - K20R, S68N, E194K, G196R, R199K, L210V, L214F
47 K65R - S68N, G196R
265 (no CD8) K65R - K20R, S68N, G196R, L214F, Q248N
296 (no Tx) K65R - K20R, S68N, G196R, L214F, Q248N
30581 20 (Tx) - - V75I, E194K, G196R,
22 - - V75L, G196R, L214L/F
24 - K70K/E V75L, G196R
28 - K70E G196R, M357T
32 K65R - G196R, L214F, M357T
40 K65R - S68G, G196R, L214F
53 K65R K70T S68G, F116W
84 K65R K70T S68G, A98G, F116W, P150S, I159V, R172I, V179G, Q222L
209 K65R K70T E40Q, K45Q, S68G, T69I, A98G, F116W, I178M, G196R, K219R, K275R, 
R277K, M357S
30842 20 (Tx) - - V75L, E194K, G196R,
22 - - V75L, G196R, L214F
24 - K70E G196R, L214F
28 K65R/K - G196R, L214F
32 K65R - S68N, G196R, L214F, N218E, M357T
40 K65R - E194K, G196R, L214F
42 K65R - Y115F, Y181C, K219E
30845 20 (Tx) - - V75I, E169K, E194K, G196R,
21 - - V75V/L, G196R
22 - - T69N/T, W88S, G196R, L214F
24 - K70K/E G196R, K275R
28 K65K/R K70E G196R
32 K65R G196R, L214F, K275R, M357T
36 K65R S68G, W88S, G196R, M357T
40 K65R - S68G, W88S, E194K, G196R, L214F
53 K65R - S68G, W88S, Y115F
84 K65R K70N S68G, W88S, A98G, Y115F, P150S, D177N
149 K65R K70N K11N, V21I, K22R, M41L, S68G, W88S, Y115F, F116W, V118I, H221Y, 
V245M, K275R, R277K, I275R, M357T
All data were obtained from PBMC isolates by population sequencing methods. (Tx) indicates the start of tenofovir therapy. (no CD8) and (no Tx) indicate the viral rebound 
during CD8+ cell depletion experiment and tenofovir withdrawal experiment of animal 30577, respectively.
Table 1: Mutations in RT detected in virus isolated from RT-SHIV infected macaques. (Continued)Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
Page 11 of 22
(page number not for citation purposes)
Kinetics of K70E and K65R RT mutants during tenofovir therapy Figure 6
Kinetics of K70E and K65R RT mutants during tenofovir therapy. Twelve RT-SHIV infected macaques were started 
on tenofovir treatment 5 months after infection. Real-time PCR technology was used to quantitate K65R and K70E RT mutants 
in plasma samples; values are expressed as percentage of total viral RNA copy number. At the onset of tenofovir therapy (i.e, 
baseline, BL), no K65R and K70E virus could be detected. The red and blue circles indicate the first detection of K70E and 
K65R, respectively; weeks indicate weeks of tenofovir treatment.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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2 weeks of treatment) to 410,000 copies per ml at 8 weeks
of treatment (i.e., 28 weeks of infection), but then gradu-
ally declined again and became undetectable (< 30 viral
RNA copies/ml) from 53 weeks of infection onwards (i.e.,
33 weeks of tenofovir treatment; Fig. 8). During contin-
ued tenofovir treatment, there was a gradual increase of
CD4+ T lymphocyte values to normal pre-infection levels
(percentage of CD4+ T lymphocytes: 30–39%; CD4+/
CD8+ T-cell ratio 1.25–1.75; absolute CD4+ T lym-
phocyte counts: ≥ 700 per μl; Fig. 3, 8).
Similarly to our previous studies in tenofovir-treated
SIVmac251-infected macaques [20], we investigated if this
suppressed viremia of K65R virus in animal 30577 during
Segregation of K65R and K70E mutations, and linkage of codon 68 mutations with K65R Figure 7
Segregation of K65R and K70E mutations, and linkage of codon 68 mutations with K65R. Plasma viral RNA sam-
ples in which real-time PCR assays detected both K65R and K70E mutations were analyzed further; representative samples are 
shown. Panel A: animal 30007, week 8 of tenofovir treatment (see Figure 6). Population sequencing revealed a mixture of wild-
type and mutant variants at both codons 65 and 70 (top graph); the bar indicates the codon reading frame. The selective ampli-
fication of virus sequences containing 65R or 70E by real-time PCR allowed for their enrichment from the virus background 
quasispecies. Direct sequencing of the mutation-specific amplicons revealed that the 65R amplicon (AGA, arginine) had wild-
type sequence at codon 70 (AAA, lysine; middle graph), while the 70E amplicon (GAA, glutamic acid) had wild-type at codon 
65 (lysine, AAA; bottom graph). Thus, the K65R and K70E mutations were on separate viral genomes. Panel B: animal 30478, 
week 12 of tenofovir treatment. The mutation-specific amplicons from this specimen also exhibited segregation of K65R and 
K70E. The sequence of the 65R amplicon demonstrated mutations at codon 68 (middle graph), while the 70E amplicon had 
wild-type sequence (AGT, serine) at codon 68 (bottom graph). The presence of mixtures is indicated (M is A or C; R is A or 
G).Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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Importance of both CD8+ cell-mediated immune responses and continuous tenofovir treatment in RT-SHIV infected animal  30577 Figure 8
Importance of both CD8+ cell-mediated immune responses and continuous tenofovir treatment in RT-SHIV 
infected animal 30577. As indicated in Figure 3, animal 30577 was inoculated with RT-SHIV (time zero). Panel A and B rep-
resent viral RNA levels in plasma, and cell counts in peripheral blood (as measured by flow cytometry), respectively. Tenofovir 
treatment was started at 20 weeks of infection (vertical dotted line), resulting in an initial rapid 47-fold reduction of viremia 
(with estimated half-life of productively infected cells of 1.3 days). Despite an initial rebound associated with emergence of 
K70E followed by K65R viral mutants (table 1; Fig. 6), viremia became undetectable at 55 weeks of infection. At 264 weeks of 
infection, CD8+ cells were depleted using administration of 3 doses of cM-T807, while tenofovir treatment was continued (at 
a maintenance regimen of 2.5 mg/kg once daily). After a ~6 log increase in viremia (consisting of K65R virus), virus levels 
decreased rapidly (with estimated half-life of productively infected cells of 0.9 days) as soon as CD8+ cells started to return. At 
289 weeks of infection, tenofovir treatment was interrupted for 9 weeks, and when viremia increased, restarted at the same 
regimen. The increased viremia during both experimental manipulations demonstrate that both CD8+ cells and continued ten-
ofovir therapy were required for optimal suppression of viremia.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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prolonged tenofovir treatment was due to (i) a replica-
tion-impaired phenotype of the K65R mutant in this ani-
mal, (ii) strong CD8+ cell-mediated antiviral immune
responses, and/or (iii) residual antiviral activity of the ten-
ofovir regimen. Accordingly, 2 sequential experiments
were performed, in which either CD8+ cells or tenofovir
treatment were removed. In the first experiment, CD8+
cells were temporarily depleted via administration of 3
doses of the anti-CD8 antibody cM-T807 at 263 weeks of
infection (~5 years of infection, and 4 years of undetecta-
ble viremia). Tenofovir treatment was continued at a sta-
ble maintenance regimen (2.5 mg/kg once daily,
subcutaneously) during this period. Following the first
dose of cM-T807, CD8+ T cells and NK cells were undetec-
table or very low (< 1% of lymphocytes; < 5 cells per μl)
in peripheral blood for 3 weeks. Viral RNA levels became
again detectable in plasma 10 days after the first cM-T807
injection, and peaked to 22 million RNA copies/ml on
day 17 (Fig. 8). This dramatic increase in viral RNA levels
in plasma was accompanied by an increase in infectious
virus titers in PBMC, from undetectable (< 1) to 3,160
TCID50 per million PBMC on day 17 (data not shown).
Real-time RT-PCR revealed that the plasma viral RNA at
peak viremia consisted exclusively of K65R viral mutants,
with no detection of the K70E mutation or wild-type
sequence; this plasma viral RNA had also the S68N and
G196R mutations; virus isolated from PBMC at peak
viremia also had the expected K65R mutation, with rela-
tively few other RT mutations compared to virus isolated
4 years earlier (table 1). When the CD8+ T lymphocytes
and NK cells returned, plasma viral RNA levels and cell-
associated infectious virus levels declined rapidly to unde-
tectable baseline levels (< 30 RNA copies per ml plasma
and < 1 TCID50 per million PBMC, respectively). The ini-
tial phase of very rapid decline of viral RNA levels during
the return of CD8+ cells indicates a half-life of produc-
tively infected cells of 0.9 days, suggesting high antiviral
potency of the returning CD8+ cells (Fig. 8). This transient
rebound in viremia following CD8+ cell depletion was
associated with a progressive decrease in CD4+ T lym-
phocyte counts (nadir of 199 cells per μl), which returned
to normal levels (> 500 per μl) upon the reduction of
viremia to undetectable levels (Fig. 8).
To determine if continued tenofovir treatment was
required to maintain undetectable viremia in animal
30577, tenofovir treatment was interrupted at 289 weeks
(~5.5 years) of RT-SHIV infection. Five weeks later, virus
could be isolated again from PBMC, and this virus had the
K65R and the same other RT mutations (including S68N)
that were also detected during the viral rebound of the
CD8+ depletion experiment (table 1). Starting 5 weeks
after tenofovir withdrawal, viral RNA levels in plasma also
became detectable again and increased slowly (Fig. 8).
Real-time PCR performed on the plasma sample collected
9 weeks after tenofovir withdrawal (which had a viral load
of 910 RNA copies per ml) revealed K70E but no K65R.
Further sequencing of the plasma RNA revealed that this
K70E virus had also G196R, but not S68N; although it did
not have I178M, this K70E virus therefore resembled the
virus that was detected early after the start of tenofovir
treatment (see table 1, week 24 isolate). Nine weeks after
tenofovir withdrawal (when viremia was 910 RNA copies/
ml), tenofovir was restarted at the same regimen; both the
PBMC-associated infectious virus levels and the plasma
viral RNA levels returned to persistently undetectable lev-
els (< 30 copies/ml) within one week of treatment (Fig. 8).
Thus, continued tenofovir therapy was required to main-
tain optimal suppression of K65R and K70E viremia in
this animal.
Discussion
The current report provides further insights into the many
aspects of chronic tenofovir therapy, including the
sequential emergence and implications of K70E and K65R
viral mutants. These data are important and timely, con-
sidering (i) the increased use of tenofovir in HAART regi-
mens, and (ii) the ongoing clinical trials which investigate
if chronic administration of tenofovir can protect high-
risk groups against HIV infection, particularly since no
prophylactic strategy is likely to be 100% effective [37].
The present data largely confirm the observations made
previously with tenofovir in the SIVmac251 model [20],
but the use of RT-SHIV led to novel findings, such as the
transient detection of K70E viral mutants early after the
start of tenofovir therapy. The advantage of an animal
model is that it allows the control of many variables and
experimental procedures (such as monotherapy and
CD8+ cell depletions) that enable the study of mecha-
nisms that would otherwise be difficult to unravel, and
that are relevant to the clinical use of tenofovir-containing
regimens in HIV-1 infected humans.
In the current study, intravenous inoculation of the first
group of macaques with a high dose of RT-SHIV led to
persistent viremia with set-point of 106 to 107 viral RNA
copies per ml plasma, higher than that observed in some
previous studies that used a lower virus inoculum
[26,28,31]. Sequential in vivo passages of RT-SHIV did not
lead to detectable changes in virulence, as determined by
viremia, and CD4+ and CD8+ T lymphocyte counts. It is
plausible that after the high-dose intravenous inocula-
tion, the potential virulence was already maximized, as
viremia levels were similar to those commonly observed
with the parental SIVmac239 virus [38,39].
Others have reported that when RT-SHIV infected
macaques were started on short-term tenofovir treatment
(30 mg/kg, subcutaneously SID) either during acute
viremia or during chronic infection (when viral set-pointsRetrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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were 104 to 106 RNA copies/ml), viremia was rapidly
reduced in all animals [26,29]. In the current study, the
early virologic response to tenofovir was more variable,
possibly because of the lower tenofovir dose (10 mg/kg)
and the higher pre-therapy viral RNA set-points (~106 to
107 RNA copies/ml). In the present study, a higher pre-
therapy viral RNA set-point (an indirect measure of
weaker antiviral immune responses at the onset of treat-
ment) correlated with a reduced early virologic response
to tenofovir.
The expression of the MHC Class I allele Mamu-A*01 has
previously been associated with a better immunologic
control of the parental SIVmac239 virus, and antiviral
CD8+ CTL responses directed against Mamu-A*01-
restricted epitopes (including in Gag and Tat) were found
to be dominant during SIVmac239 infection [40,41]. In
the current RT-SHIV study, which had the limitation of
small animal groups, there was no difference in viremia
between Mamu-A*01 positive and -negative animals
before the onset of tenofovir therapy. However, animals
which expressed the Mamu-A*01 allele had a more pro-
nounced drop in viremia during the first 4 weeks of teno-
fovir therapy than Mamu-A*01-negative animals. This
observation suggests that any role of Mamu-A*01-
dependent antiviral immune responses in attempting to
control viremia was transiently unmasked or rescued by
the concomitant tenofovir treatment. These findings are
consistent with previous observations (including from
studies that used CD8+ cell depletion) that demonstrated
that the early virologic response to tenofovir and other
drugs in SIV and env-SHIV-infected macaques is highly
dependent on the strength of antiviral immune responses
[20,22,42,43]. Evidence from human trials also suggests a
role of the immune system in determining the efficacy of
drug treatment, as lower baseline viral RNA levels, a better
status of the immune system, and certain MHC class II
genotypes are predictive of a faster and/or more sustained
response to HAART [44-49]. In HIV-1 infected humans,
the reduction in viral RNA levels following the start of ten-
ofovir therapy was larger and faster in treatment-naive
patients than in treatment-experienced patients who gen-
erally had lower CD4+ T cell counts [50-52]. In the current
study with macaques, RT-SHIV infection led to a reduc-
tion of CD4+ cell counts and percentages in peripheral
blood, but an unexpected finding was that lower pre-ther-
apy baseline values of percentage CD4+ T cells were asso-
ciated with lower RNA levels, and a better early virologic
response to tenofovir. While our study was not designed
to unravel the mechanisms linking viremia and CD4+ T
cell counts in peripheral blood, this observation mainly
highlights that CD4+ T cell numbers in the peripheral
blood of the macaques were not a very reliable marker of
immunocompetence at this intermediate stage of RT-
SHIV infection.
When RT-SHIV infected macaques were started on tenofo-
vir, there was a rapid selection for viral mutants with a
K70E RT mutation. The K70E RT mutants were subse-
quently replaced by K65R RT mutants. Similarly to obser-
vations with HIV-1 [53,54], when K70E and K65R RT-
SHIV mutants were both detected in plasma, these 2
mutations were found on separate viral genomes. The
K70E mutation has previously been described in HIV-1
after selection pressure with adefovir in vitro and in vivo
[55,56]. The K70E mutation has only been described in a
few cases of tenofovir-treated HIV-1 infected persons,
although it is possible that a more systematic investiga-
tion of early samples following tenofovir therapy may
reveal a higher frequency [54,57,58]. Because the regimen
of these HIV-1 infected persons included also other RT
inhibitors (e.g., abacavir and lamivudine; [54,57]), the
detection of K70E virus in macaques during tenofovir
monotherapy is the first evidence that tenofovir can select
directly for this K70E mutation in vivo. In the current
macaque study, it is possible that a higher precursor muta-
tion frequency at codon 70 (but still below the 0.2%
detection limit in the baseline samples) may have predis-
posed for selective outgrowth of first variants with the
K70E mutation which, in vitro, confers only a relatively
minor fitness cost and minimal resistance to tenofovir
(ranging from no effect to ≤ 2-fold reduced susceptibil-
ity)[2,56,59]. These K70E mutants were then rapidly
replaced by K65R mutants which in the absence of drug
are more replication-impaired in vitro than K70E mutants,
but in the presence of tenofovir could outgrow K70E
mutants due to a slightly higher level (~4–5 fold) of in
vitro resistance to tenofovir [56,60]. This replacement of
variants based on replicative capacity would be similar to
observations in lamivudine-treated patients, where differ-
ences in pre-therapy frequencies of codon 184 mutants
also appear to explain the transient detection of M184I
mutants, which are then replaced by the more fit M184V
mutants [61]. While previous studies in macaques used
usually higher tenofovir regimens (20–30 mg/kg subcuta-
neously SID; [20,62-64]), it is unclear if the 10 mg/kg ten-
ofovir regimen of the current study may also have
contributed to a transient outgrowth of K70E mutants that
were subsequently, when intracellular drug levels built up
to steady-state levels, replaced by the more resistant K65R
mutants.
The emergence of K65R RT-SHIV mutants during tenofo-
vir treatment was accompanied by an accumulation of
other RT mutations, believed to be compensatory muta-
tions that improve the replicative capacity of K65R virus.
Many of these mutations have been described previously
with or without K65R in HIV-1 infected persons receiving
tenofovir-containing or other HAART regimens, and some
(such as M41L) have been reported to contribute to aRetrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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reduced virologic response to tenofovir when in combina-
tion with other RT mutations [5,8,14,34,59,65,66].
The clinical implications of the K70E and K65R RT-SHIV
mutants were similar to those reported previously for
K65R SIVmac251 mutants [19,20,22]. In the current RT-
SHIV study, because treatment was initiated after 20
weeks of persistently high viremia, the immune system
was already compromised. In such situation, for the
majority of animals, CD8+ cell-mediated immune
responses were not sufficient to assist in suppressing
viremia to very low levels especially once the RT mutants
emerged. Following the emergence of such viral mutants,
plasma viremia of most animals increased and stabilized
to a level on average 10-fold below pre-therapy baseline
values, indicating some residual therapeutic benefit. This
lower viremia may be due to a combination of several fac-
tors, including decreased replicative capacity of the K65R
mutants (especially of the early mutants, prior to the accu-
mulation of presumed compensatory mutations), some
residual antiviral effects of the tenofovir regimen, and/or
antiviral immune responses (see further). These findings
are consistent with observations in tenofovir-treated
humans, where the detection of K65R is not always asso-
ciated with a virologic rebound [1,5], and the detection of
the K65R mutation with a virologic rebound was most
likely in patients with high baseline RNA levels and low
CD4+ cell counts [3,6,9,67]. The findings of a ~10-fold
reduced viremia in most K65R RT-SHIV infected animals
during continued tenofovir monotherapy are reminiscent
of observations in people who are infected with M184V
mutant HIV-1, and for whom continuation of lamivudine
monotherapy is associated with a ~2- to 4-fold reduction
in viremia and clinical benefits [68-73]. In contrast, for
some other drugs (such as nevirapine), the emergence of
viral mutants has been associated with a rebound of
viremia to pre-therapy levels [74].
While 11 of the 12 animals maintained persistent viremia
and eventually developed disease, animal 30577 was an
exception. Further research is needed to determine which
host and/or viral factors (e.g., unique genotypes) may
have been responsible for this different outcome, as ani-
mal 30577 was initially indistinguishable from the other
animals based on our limited panel of pre- and early post-
therapy markers (virus levels, CD4+ and CD8+ lym-
phocyte numbers, and emergence of RT mutations). Ani-
mal 30577 first had a rapid 47-fold reduction in viremia
within 2 weeks of treatment but then had a 10-fold
increase in viremia above nadir levels by 8 weeks of treat-
ment, that was associated with the emergence of K70E fol-
lowed by K65R viral mutants. Several human studies in
which tenofovir-containing HAART regimens were initi-
ated in antiretroviral-naïve patients used virologic criteria
(< 2 log reduction in viral RNA by week 8; rebound of ≥
0.5–1 log RNA copies/ml above nadir [6,11,67]) accord-
ing to which this viral RNA pattern in animal 30577
would have been classified as a "virologic non-response"
or "treatment failure", and tenofovir treatment would
have been withdrawn. However, despite the initial viral
RNA rebound in this macaque, continued tenofovir treat-
ment led to a gradual decrease of viremia to undetectable
levels after 8 months of therapy. Thus, our data suggest
that further studies (including retrospective analysis of
already available samples) are warranted to investigate the
potential clinical benefits of continued tenofovir therapy
in HIV-1 infected patients even after a partial rebound
with the detection of K65R viral mutants, as it is possible
that some individuals may eventually suppress viremia
again [22].
The CD8+ cell depletion experiment demonstrated that
the reduced viremia in tenofovir-treated animal 30577
was mediated largely by CD8+ cells, because removal of
CD8+ cells caused a transient ~1 million-fold increase of
K65R viremia, to peak levels similar to those observed
during acute viremia with wild-type RT-SHIV (Fig. 3, 8).
Because a stable tenofovir treatment regimen was contin-
ued during the CD8+ cell depletion experiment, this dra-
matic increase in K65R viremia, which was associated
with a reduction in CD4+ T lymphocyte counts, indicates
that in the absence of CD8+ cells, tenofovir treatment
alone had insufficient inhibitory activity against K65R RT-
SHIV, and this virus had good replicative capacity and vir-
ulence. This suggests that, at least when accompanied by
other RT mutations, a potential attenuating effect of the
K65R mutation on viral replicative capacity is by itself
insufficient to explain the reduced viremia during tenofo-
vir therapy. The demonstration of the direct causality
between CD8+ cell-mediated immune responses and sup-
pressed K65R viremia in tenofovir-treated animal 30577
is important, as it helps to explain observations in
humans, where strong cell-mediated immune responses
were associated with the maintenance of low-level viremia
in HAART-treated individuals with drug-resistant HIV-1
[75-78].
Because the cM-T807 antibody depletes both the
CD3+CD8+ T lymphocytes and CD3-CD8+ NK cells, the
relative contribution of these 2 cell populations to the
immune-mediated suppression of viremia in animal
30577 could not be determined in the current experiment.
NK cells are also effector cells of antibody-dependent cel-
lular cytotoxicity (ADCC). In an in vitro assay that meas-
ures antibody-dependent cell-mediated virus inhibition,
plasma samples of animal 30577 and of tenofovir-treated
SIVmac251-infected animals that similarly suppressed
K65R viremia to undetectable levels were found to have
high antiviral activity in the presence of PBMC effector
cells [79]. In these long-term tenofovir-treated SIV or RT-Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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SHIV infected animals with undetectable viremia, the
antiviral immune responses must be unusually strong and
broad, as immune-escape mutants have not emerged even
after 6 to 11 years of tenofovir treatment ([20,43]; unpub-
lished data). Further elucidation of these strong antiviral
immune responses (including effector frequency, epitope
recognition, etc.) may aid the development of novel
immunotherapeutic strategies that combine the strengths
of antiviral drugs and the immune system to indefinitely
delay disease progression in HIV-infected persons.
Despite this important role of CD8+ cells, continued
administration of tenofovir was still required to maintain
maximal suppression of K65R viremia in animal 30577;
in other words, both antiviral immune responses and ten-
ofovir were needed. This is similar to previous observa-
tions in tenofovir-treated animals that were infected with
K65R SIV mutants [20]. A recent report also demonstrated
that both antiviral immune responses (induced by prior
immunization) and short-term tenofovir administration
were required to protect macaques against infection after
intravenous inoculation with a high dose of a virulent
K65R SIV isolate [80]. For RT-SHIV infected animal
30577, the viral rebound following withdrawal of tenofo-
vir therapy was relatively slow (in comparison to the more
rapid and dramatic rebound during CD8+ cell depletion),
and consisted of K65R in PBMC-associated infectious
virus, but K70E in plasma viral RNA. The reason for this
discrepancy in mutations is unclear, but it is plausible that
both sources of virus reflect distinct compartments, where
differences in the relative role and strength of immuno-
logic and pharmacologic factors may affect virus replica-
tion differently upon tenofovir withdrawal. As discussed
previously, it is unclear whether the need of continued
tenofovir treatment to achieve optimal inhibition of K65R
virus replication is due to residual direct antiviral activity
of the tenofovir regimen against these mutants (e.g., in
antigen-presenting cells), and/or to potential immu-
nomodulatory effects of tenofovir (such as priming of IL-
12 secretion) that promote the generation and mainte-
nance of strong antiviral immune responses [20,81]. It is
important to remember that the effects of antiviral
immune responses during drug therapy are not mutually
exclusive of the effects of residual drug activity and/or
reduced replicative capacity of mutant virus. In particular,
even a partial inhibition of virus replication by the drug
regimen, or a minor decrease in replicative capacity, can
have a major impact on viremia if it provides more oppor-
tunity for effective antiviral immune responses to kill pro-
ductively infected cells prior to the major viral burst.
While our macaque studies modeled only the responses to
tenofovir monotherapy, such considerations may be even
more relevant for HAART-treated humans, as the combi-
nation of the K65R mutation with some other drug-
selected mutations can further decrease viral replication
fitness and affect drug susceptibility (including restored
susceptibility) to tenofovir or other drugs of the HAART
regimen, which may offer additional opportunities for
antiviral activity.
Conclusion
The current findings with RT-SHIV are consistent with but
also extend previous observations on the K65R mutation
in the SIV model [20,22,80], with the novel observation
of the tenofovir-selected K70E mutation (which was not
detected by population sequencing in tenofovir-treated
SIVmac251-infected macaques). The observations in
macaques suggest that for persons infected with K65R
HIV-1, both immune-mediated and drug-dependent anti-
viral activities may play a role in controlling viremia, and
that even in the presence of K65R virus, continuation of
tenofovir treatment as part of HAART may be beneficial,
particularly when assisted by antiviral immune responses.
In other words, the detection of K65R may by itself not be
a valid reason to withdraw tenofovir from the patient's
regimen, unless more effective salvage regimens, which
are also feasible in terms of cost, toxicity and compliance
are available. While preliminary data already suggest the
virologic benefits of including tenofovir in drug regimens
for HIV-1 infected patients with K65R mutants [82,83],
additional long-term studies are warranted to determine
also the potential clinical benefits of continuing tenofovir
therapy in the presence of K65R mutants. Such informa-
tion is also relevant to develop treatment guidelines for
resource-poor areas, where access to 2nd or 3rd line anti-
HIV drugs may be limited, and regular monitoring of virus
levels and drug resistance (such as K65R) is not always
feasible. Simple treatment strategies for which decisions
to alter the regimen would be less dependent on frequent
monitoring of such laboratory parameters will be more
practical and affordable, and can thus benefit the largest
number of people.
Methods
Animals
All rhesus macaques (Macaca mulatta) were juvenile ani-
mals from the type D-retrovirus-free and SIV-free colony
at the California National Primate Research Center
(CNPRC), and were housed in accordance with American
Association for Accreditation of Laboratory Animal Care
standards, with strict adherence to the "Guide for the Care
and Use of Laboratory Animals" [84]. For blood collec-
tions, animals were immobilized with 10 mg/kg intra-
muscular ketamine-HCL (Parke-Davis, Morris Plains, NJ,
USA). Complete blood cell counts were measured by
using an automated electronic cell counter (Baker 9000;
Serono Baker Diagnostics); differential counts were deter-
mined manually.Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
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In vitro propagation of RT-SHIV
An infectious cell-free stock of RT-SHIV (which contains
the RT of HIV-1 IIIB clone HXBc2; [24]) was prepared fol-
lowing transfection of CEMx174 cells by electroporation,
as described previously [31]. Aliquots of cell-free superna-
tants were stored frozen at -130°C. This RT-SHIV stock
had a titer of 105 50% tissue culture infectious doses
(TCID50) per ml. This RT-SHIV stock had the T to C sub-
stitution at position 8 of the SIV tRNA primer binding site,
which is necessary for rapid replication of RT-SHIV in vivo
[85].
Animal inoculation and in vivo passage of RT-SHIV
A first group of 3 animals (group A; Fig. 1) was inoculated
intravenously with 1.0 ml of undiluted virus (i.e., 105
TCID50). Equal volumes of cryopreserved EDTA-anticoag-
ulated plasma collected from the 3 animals at 2 weeks of
infection were thawed, pooled and 0.6 ml was adminis-
tered intravenously to 4 new animals (group B; Fig. 1).
Similarly, EDTA-anticoagulated plasma collected from
these 4 animals 2 weeks after virus inoculation was
pooled and 0.6 ml was administered intravenously to
another 5 animals (group C).
Preparation and administration of tenofovir
Tenofovir (Gilead Sciences) was suspended in distilled
water, dissolved by the addition of NaOH to a final pH of
7.0 and concentration of 60 mg/ml, filter sterilized (0.2
μm; Nalgene), and stored at 4°C. Starting at 20 or 21
weeks after RT-SHIV inoculation, tenofovir was adminis-
tered subcutaneously into the back of the animal at a once
daily dosage regimen of 10 mg/kg body weight, with dos-
age changes described in the results section. Animals were
monitored regularly by chemistry panels and urinalysis to
monitor for renal toxicity that occurs with prolonged
high-dose tenofovir regimens, and make the necessary
dosage adjustments [36].
Administration of cM-T807
CD8+ cells were depleted using the previously described
cM-T807 antibody [86,87]; a total of 20 mg/kg body
weight was administered in 3 doses: 10 mg/kg subcutane-
ously on day 0, and 5 mg/kg intravenously 3 and 7 days
later. No adverse effects were observed following cM-T807
administration.
Quantitation of plasma viral RNA
Viral RNA levels in plasma were quantified using a real-
time reverse transcription-polymerase chain reaction (RT-
PCR) assay for SIV gag, described previously [88,89]. With
the available plasma volumes, the sensitivity was 30 RNA
copies/ml.
Virus isolation
Infectious virus was isolated in cultures of peripheral
blood mononuclear cells (PBMC) with CEMx174 cells
and subsequent p27 core antigen measurement, accord-
ing to methods previously described [90]. Levels of infec-
tious virus in PBMC and plasma were determined by a
limiting dilution assay [90].
Drug susceptibility assays
Phenotypic drug susceptibilities of RT-SHIV isolates were
characterized by a previously described assay based on a
dose-dependent reduction of viral infectivity [19,91].
Sequence analysis of RT-encoding region
Infected CEMx174 and PBMC co-cultures were harvested
as soon as culture supernatants were positive by antigen
capture ELISA. Genomic DNA was extracted and used for
nested PCR; amplicons were purified with a PCR purifica-
tion kit (QIAGEN) and used for DNA sequencing accord-
ing to methods and with primers described previously
[25,31]. This method can detect the presence of a 20%
subpopulation.
Real-time polymerase chain reaction (PCR) for sensitive 
detection of K65R and K70E in plasma RT-SHIV RNA
Sensitive testing for the K65R and K70E mutations was
performed using real-time PCR-based methodologies as
described previously [92]. Briefly, a 763 nucleotide tem-
plate of RT-SHIV (n.t. 58 to 821 in RT) was first amplified
by RT-PCR using the HIV-1 RT primer RTP-REV (5'-ATC
CCT GCA TAA ATC TGA CTT GC) for the reverse tran-
scriptase step followed by addition of forward primer
RTP-F2 (5'-AAA GTT AAA CAA TGG CCA TTG ACA G) for
PCR amplification.
The real-time PCR reactions were performed in duplicate
using 2 μl of the RT-PCR products for both the total virus
copy and mutation-specific tests. Total SHIV RT templates
were detected with the primers ComFWD and ComREV,
which span n.t. 258–420 in RT, along with the common
probe 1. The reactions for detecting the K65R mutation
involved the mutation-specific primer HIV-RT 65R.FWD
with the primer 65R.REV and FAM-labeled probes mix-
ture, 1P (80%) and 2P (20%). The K70E test used the
mutation-specific primer 70E.REV with the primer
70.FWD and probe 70.2P. Differences in total copy and
mutation-specific amplification curves (ΔCT) of ≤9 or ≤
10 cycles indicated the presence of 65R and 70E, respec-
tively. These assay cutoffs allowed mutant viruses to be
detected at frequencies ≥ 0.4%.
Mutation linkage analysis
To evaluate the interplay of the mutations during emer-
gence, the positive mutation-specific amplicons were
directly sequenced using the primers 65-118SEQ.1R (5'-Retrovirology 2007, 4:25 http://www.retrovirology.com/content/4/1/25
Page 19 of 22
(page number not for citation purposes)
CTA GGT ATG GTA AAT GCA GTA TAC TTC CT) and RT-
SEQ.2F (5'-AAG GAA GGG AAA ATT TCA AAA ATT GGG
CC) for the K65R amplicon and K70E amplicon, respec-
tively. The overlapping amplicon sequences allowed for
visualization of the adjacent codons.
Detection of SIV-specific immune responses
The ELISA to detect SIV-specific immunoglobulin G (IgG)
in plasma samples was performed as described previously
[22].
Lymphocyte phenotyping
Initially, 3-color flow cytometry techniques were used to
detect CD3, CD4, CD8 and CD20 with fluorochrome-
conjugated antibodies described previously [93,94]. Start-
ing at approximately 145 weeks of infection, 4-color flow
cytometry techniques were used, consisting of a single
tube containing antibodies to CD3, CD4, CD8 and CD20,
as described previously [20]. CD4+ T lymphocytes and
CD8+ T lymphocytes were defined as CD3+CD4+ and
CD3+CD8+ lymphocyte populations, respectively. B lym-
phocytes were defined as CD3-CD20+ lymphocytes. NK
cells were defined as CD3-CD8+ lymphocytes. During the
CD8+ cell depletion experiment, the anti-CD8 antibody
was replaced by the DK25 clone (DAKO, Carpinteria, Cal-
ifornia) conjugated to FITC (and combined with anti-
CD3-PerCP, anti-CD4-PE and anti-CD20-APC as decribed
previously [20]).
Genetic assessment of MHC class I alleles
DNA extracted from lymphoid cells (with QIAamp® DNA
mini kit, QIAgen, Valencia, CA) was used to screen for the
presence of the major histocompatibility complex (MHC)
class I alleles Mamu-A*01 and Mamu-B*01, using a PCR-
based technique [95,96]. The frequency of Mamu-A*01
and Mamu-B*01 alleles in the CNPRC rhesus macaque
colony is approximately 25%.
Criteria for euthanasia and animal necropsies
Euthanasia of animals with simian AIDS was performed
when clinical observations indicated a severe life-threat-
ening situation for the animal, as described previously
[22]. A complete necropsy with a routine histopathologic
examination of tissues was performed. Tissues were fixed
in 10% buffered formalin, embedded in paraffin, sec-
tioned at 6 μm, stained with hematoxylin and eosin, and
examined by light microscopy.
Statistical analysis
Statistical analyses were performed with Prism Version 4.0
and Instat Version 3.0a (GraphPad Software Inc. San
Diego, CA). All statistical analyses of viral RNA levels in
plasma were performed after log-transformation of the
values.
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